Travere CEO exercises options, sells 60K shares

Travere Therapeutics CEO Eric M. Dube exercised stock options covering 60,000 shares of common stock at $15.46 per share on April 1, 2026, then sold the same 60,000 shares in the open market.

Rhea-AI Filing Summary

Travere Therapeutics CEO Eric M. Dube exercised stock options covering 60,000 shares of common stock at $15.46 per share on April 1, 2026, then sold the same 60,000 shares in the open market.

The sales were split between 34,902 shares at $30.55 and 25,098 shares at $31.46, executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2025. After these transactions, Dube directly holds 432,886 shares of Travere common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 60,000 shares ($928K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Dube Eric M

Role CHIEF EXECUTIVE OFFICER

Sold 60,000 shs ($1.86M)

Approx. gross sale proceeds $1.86M

Approx. exercise cost $928K

Approx. pre-tax spread $928K

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	60,000	$0.00	$0.00
Exercise	Common Stock	60,000	$15.46	$928K
Sale	Common Stock	34,902	$30.55	$1.07M
Sale	Common Stock	25,098	$31.46	$790K

Holdings After Transaction: Employee stock option (right to buy) — 0 contracts (Direct); Common Stock — 432,886 shares (Direct)

Footnotes (4)

1. F1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.
2. F2. The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
3. F3. The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
4. F4. The stock option is fully vested and exercisable.

Key Figures

Options exercised: 60,000 shares Exercise price: $15.46/share Shares sold at $30.55: 34,902 shares +4 more

7 metrics

Options exercised 60,000 shares Employee stock option exercise at $15.46 on April 1, 2026

Exercise price $15.46/share Exercise or conversion price of employee stock option

Shares sold at $30.55 34,902 shares Open-market sale at weighted average $30.55 on April 1, 2026

Shares sold at $31.46 25,098 shares Open-market sale at weighted average $31.46 on April 1, 2026

Total shares sold 60,000 shares Combined open-market sales on April 1, 2026

Post-transaction holdings 432,886 shares Common stock directly owned after transactions

Option expiration January 31, 2030 Expiration date of the exercised employee stock option

Key Terms

Employee stock option, Rule 10b5-1(c), weighted average sale price, open-market sale, +1 more

5 terms

Employee stock option financial

"security_title: "Employee stock option (right to buy)""

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

Rule 10b5-1(c) regulatory

"written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $30.55"

open-market sale financial

"transaction_action: "open-market sale" for Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Travere Therapeutics (TVTX) CEO Eric Dube report?

Eric Dube reported exercising options for 60,000 Travere shares at $15.46 and selling those 60,000 shares in two open-market transactions at $30.55 and $31.46 per share on April 1, 2026.

How many Travere Therapeutics (TVTX) shares does the CEO own after this Form 4?

After the reported transactions, CEO Eric Dube directly owns 432,886 shares of Travere Therapeutics common stock. This figure reflects his holdings following the option exercise of 60,000 shares and subsequent sales totaling 60,000 shares on April 1, 2026.

Were Eric Dube’s Travere Therapeutics (TVTX) share sales pre-planned under Rule 10b5-1?

Yes. The filing states the sales were made under a written trading plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements. Such plans pre-schedule trades, making transaction timing more routine rather than discretionary.

At what prices did the Travere Therapeutics (TVTX) CEO sell his shares?

Eric Dube sold 34,902 shares at a weighted average price of $30.55 and 25,098 shares at a weighted average price of $31.46. Footnotes note price ranges around each average and offer full price breakdowns upon request.

What stock option did the Travere Therapeutics (TVTX) CEO exercise in this filing?

The CEO exercised a fully vested employee stock option granted on January 31, 2020 for 60,000 shares of Travere common stock at an exercise price of $15.46 per share. The option was described as fully vested and exercisable in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 05:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Eric M

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M		60,000	A	$15.46	492,886	D
Common Stock	04/01/2026		S(1)		34,902	D	$30.55(2)	457,984	D
Common Stock	04/01/2026		S(1)		25,098	D	$31.46(3)	432,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$15.46	04/01/2026		M			60,000	(4)	01/31/2030	Common Stock	60,000	$0	0	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.

2. The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)